MIRM NASDAQ
Mirum Pharmaceuticals, Inc.
1W: +1.2%
1M: -7.2%
3M: -25.8%
YTD: +6.7%
1Y: +20.0%
3Y: +188.1%
5Y: +403.8%
$85.56
+2.29 (+2.75%)
After Hours: $86.78 (+1.22, +1.43%)
Weekly Expected Move ±6.5%
$70
$75
$80
$86
$91
Credit Risk of going bust: lower than 58% of companies Debt: 12.3% of company value Bonds: $118.7M held by 37 funds → details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $1.13 (down 99%), Mirum Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $760.5M against a stock market value of $5.41B.
Distance to default 5.96 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $375.0M (short-term plus half of long-term), stock volatility 47.9%; Altman Z'' -7.33. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
If the stock fell to about $1.13 (down 99%), Mirum Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $760.5M against a stock market value of $5.41B.
Distance to default 5.96 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $375.0M (short-term plus half of long-term), stock volatility 47.9%; Altman Z'' -7.33. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$5.4B
52W Range63.23-130
Volume429,874
Avg Volume795,020
Beta0.49
Dividend—
Analyst Ratings
Company Info
CEOChristopher Peetz
Employees433
SectorHealthcare
IndustryBiotechnology
IPO Date2019-07-18
Websitemirumpharma.com
989 East Hillsdale Boulevard
Foster City, CA 94404
US
Foster City, CA 94404
US
650 667 4085
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Latest News
Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock Rated “Moderate Buy” by Wall Street Brokerages
Q3 EPS Estimate for Mirum Pharmaceuticals Lowered by Analyst
Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases
Mirum's Livmarli meets primary goal in phase 3 trial for itch with rare liver diseases
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Howe Jolanda | M-Exempt | 16,112 | $19.24 | 2026-10-16 |
| Howe Jolanda | M-Exempt | 16,112 | $19.24 | 2026-10-16 |
| Myers Robert Paul | A-Award | 40,000 | $86.01 | 2026-10-09 |
| Myers Robert Paul | A-Award | 25,000 | — | 2026-10-09 |
| Peetz Christopher | M-Exempt | 5,305 | $19.19 | 2026-10-06 |